Tage Honoré
Vermogen: 572 030 $ op 30-06-2026
Vermogen: 572 030 $ op 30-06-2026
Dr. Tage Honoré is an Independent Director at Vanda Pharmaceuticals, Inc., a Head-Pharmaceutical Development at Avicenna Biosciences, Inc. and a President at Aestus Partners LLC.
He is on the Board of Directors at Vanda Pharmaceuticals, Inc. Dr. Honoré was previously employed as a Chairman by Dep-Xplora ApS.
He received his graduate degree from the University of Copenhagen and a doctorate degree from the University of Copenhagen.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 04-06-2026 | 93.469 ( 0,16% ) | 572 030 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Directeur/Bestuurslid | 15-03-2023 |
Avicenna Biosciences, Inc.
Avicenna Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that intends to redesign and optimize drug candidates | Corporate Officer/Principal | 01-01-2020 |
| Bedrijven | Functie | Einde |
|---|---|---|
Dep-Xplora ApS
Dep-Xplora ApS BiotechnologyHealth Technology Develops non-steroidal anti-inflammatory drugs for arthritis pain | Voorzitter | 01-03-2019 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company, which focuses on the development and commercialization of therapies | Health Technology |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dep-Xplora ApS
Dep-Xplora ApS BiotechnologyHealth Technology Develops non-steroidal anti-inflammatory drugs for arthritis pain | Health Technology |
Avicenna Biosciences, Inc.
Avicenna Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that intends to redesign and optimize drug candidates | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau